Holen Sie sich die Stockscreener-App
2.995
0.33%
0.005
Schlusskurs vom Vortag:
$2.99
Offen:
$3.02
24-Stunden-Volumen:
223.72K
Relative Volume:
0.66
Marktkapitalisierung:
$247.32M
Einnahmen:
$351.37M
Nettoeinkommen (Verlust:
$-174.01M
KGV:
-1.4469
EPS:
-2.07
Netto-Cashflow:
$-126.94M
1W Leistung:
+3.81%
1M Leistung:
+4.17%
6M Leistung:
-8.81%
1J Leistung:
-21.67%
1-Tages-Spanne:
$2.97
$3.08
1-Wochen-Bereich:
$2.825
$3.08
52-Wochen-Spanne:
$2.60
$4.145
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Firmenname
Atea Pharmaceuticals Inc
Sektor
Branche
Telefon
857-204-8109
Adresse
225 FRANKLIN STREET, BOSTON
Vergleichen Sie AVIR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
2.995 | 247.32M | 351.37M | -174.01M | -126.94M | -2.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.65 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.21 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
651.03 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
260.10 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
256.53 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-13 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-08-10 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-01-06 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-18 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-10-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-25 | Eingeleitet | Evercore ISI | Outperform |
| 2020-11-24 | Eingeleitet | JP Morgan | Overweight |
| 2020-11-24 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-11-24 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Atea Pharmaceuticals Inc Aktie (AVIR) Neueste Nachrichten
A stock that deserves closer examination: Atea Pharmaceuticals Inc (AVIR) - uspostnews.com
Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025 - The Manila Times
JPMorgan Chase & Co. Buys 314,015 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Geode Capital Management LLC Lowers Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals Inc (AVIR) produces promising results - uspostnews.com
Financial Health Report: Atea Pharmaceuticals Inc (AVIR)’s Ratios Tell a Tale - DWinneX
Atea Pharmaceuticals (AVIR) to Reveal Phase 2 Study Results at E - GuruFocus
Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025 - GlobeNewswire
AVIRAtea Pharmaceuticals, Inc. Latest Stock News & Market Updates - Stock Titan
A better buy-in window may exist right now for Atea Pharmaceuticals Inc (AVIR) - Sete News
Layoff Tracker: Tempest Axes 80% of Workforce - BioSpace
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by Vanguard Group Inc. - Defense World
Atea Pharmaceuticals expands board, authorizes stock buyback By Investing.com - Investing.com Canada
Latham & Watkins Advises Atea Pharmaceuticals in Agreement With Radoff-JEC Group - Latham & Watkins LLP
Atea Pharmaceuticals Appoints Howard H. Berman To Board - citybiz
Atea Pharmaceuticals Announces Board Changes and Share Buyback - TipRanks
Atea Pharmaceuticals Board Approves $25 Million Share Repurchase Program - marketscreener.com
Atea Pharmaceuticals expands board, authorizes stock buyback - Investing.com
Atea Pharmaceuticals says strategic alternatives process ‘ongoing’ - TipRanks
Atea Pharmaceuticals Appoints Howard H. Berman To Board Of Directors And Announces Share Repurchase Program - marketscreener.com
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program - GlobeNewswire
Atea Pharma Doubles Down: $25M Share Buyback Plan Unveiled as Strategic Review Accelerates - Stock Titan
Morgan Stanley Issues Pessimistic Forecast for Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price - Defense World
Atea Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:AVIR - Benzinga
Atea Pharmaceuticals doses first patient in C-BEYOND, Phase 3 study - MSN
Atea Pharmaceuticals Doses First Patient In Phase 3 Trial For Chronic Hepatitis C Treatment - RTTNews
Atea Pharmaceuticals Doses First Patient in Late-Stage Study of Hepatitis C Virus Combination Regimen - marketscreener.com
Atea Pharmaceuticals Announces Dosing of First Patient in - GlobeNewswire
Atea Pharmaceuticals Announces Dosing Of First Patient In C-Beyond, Phase 3 Study Evaluating Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus - MarketScreener
Breakthrough: Atea's New 8-Week Hepatitis C Treatment Enters Final Trial Stage - Stock Titan
HighTower Advisors LLC Purchases Shares of 50,087 Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals board nominee withdrawal ahead of 2025 meeting By Investing.com - Investing.com South Africa
Atea Pharmaceuticals board nominee withdrawal ahead of 2025 meeting - Investing.com
Driver Notifies Atea Pharmaceuticals of Withdrawal of Notice of Nomination - The Manila Times
Charles Schwab Investment Management Inc. Boosts Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals takes steps to boost shareholder value By Investing.com - Investing.com South Africa
Atea Pharmaceuticals takes steps to boost shareholder value - Investing.com
Atea Pharma Reviewing Strategic Opportunities After Cutting 25% of Jobs - MarketWatch
Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value - The Manila Times
Atea's Bold Restructuring: $15M Cost Savings Plan and Strategic Review Unveiled - Stock Titan
Atea Shareholder Seeks Board Change, Plans to Nominate Directors at 2025 Annual Meeting - Marketscreener.com
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors - MarketScreener
Connor Clark & Lunn Investment Management Ltd. Raises Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals Issues Statement Regarding Director Nominations - GlobeNewswire
Atea Pharmaceuticals receives notice of director nominations from Bradley Radoff -March 21, 2025 at 05:58 pm EDT - MarketScreener
Finanzdaten der Atea Pharmaceuticals Inc-Aktie (AVIR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.01%
2.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):